Avolta stock rating upgraded to Outperform by BNP Paribas Exane

BNP Paribas Exane upgraded Avolta AG to Outperform from Neutral, raising its price target to CHF51.00 from CHF41.10. This upgrade reflects Avolta's strong first-half 2025 performance, with like-for-like revenue exceeding traffic benchmarks in key regions, and its unique large-scale segment diversification. The firm anticipates stronger revenue and margins for Avolta, also citing confidence in the eventual convergence of its Retail and Food & Beverage segments.

Analysis

BNP Paribas Exane has upgraded Avolta AG (AVOL) to Outperform from Neutral, raising its price target by approximately 24% to CHF51.00 from CHF41.10. The upgrade is underpinned by Avolta's strong first-half 2025 results, where like-for-like revenue growth in the key EMEA and North America regions surpassed corresponding traffic benchmarks, indicating solid operational execution. The analysis highlights Avolta's large-scale diversification across segments as a distinct competitive advantage not commonly found among its peers. Furthermore, BNP Paribas Exane expresses renewed confidence in the strategic thesis of an eventual convergence between Avolta's Retail and Food & Beverage divisions. This positive outlook is based on expectations of stronger revenue and margin generation without a corresponding increase in pro-forma capital expenditures, suggesting improving capital efficiency. While the article's headline references Eli Lilly, the substantive content is focused exclusively on the positive fundamental reassessment of Avolta AG.

Key Decisions for Investors

• Investors should view the BNP Paribas Exane upgrade as a significant bullish signal for Avolta AG, backed by a substantial price target increase and tangible evidence of operational outperformance.
• It is advisable to monitor Avolta's future earnings for continued evidence of like-for-like revenue growth exceeding traffic metrics and for management commentary on the progress of synergies between its Retail and Food & Beverage segments.
• Avolta's unique diversification at scale should be a key consideration in any relative valuation analysis against its peers, as this is presented as a primary driver of the positive ratings change.
• Disregard the extraneous headline regarding Eli Lilly, as the core analysis and investment thesis presented are entirely focused on the fundamental drivers for Avolta AG.